Disclosures for "Low-field, Portable Magnetic Resonance Imaging to Assess Hematoma Volume in Traumatic Brain Injury Patients"
-
Ms. Zabinska has nothing to disclose.
-
Miss Yadlapalli has nothing to disclose.
-
Miss Mazurek has nothing to disclose.
-
Ms. Parasuram has nothing to disclose.
-
Mr. Lalwani has nothing to disclose.
-
Miss Peasley has nothing to disclose.
-
Dr. Gilmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for carpl.ai. Dr. Gilmore has received personal compensation in the range of $0-$499 for serving as a Consultant for AAN. Dr. Gilmore has received research support from NIH.
-
Dr. Kim has nothing to disclose.
-
Dr. Omay has nothing to disclose.
-
Gordon Sze has nothing to disclose.
-
Sam Payabvash has nothing to disclose.
-
The institution of Dr. Sorby-Adams has received research support from American Heart Association. Dr. Sorby-Adams has received research support from Fulbright Commission Australia.
-
Dr. Iglesias Gonzalez has nothing to disclose.
-
Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DeepSpin. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chipiron. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synex. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nanalysis. Matthew Rosen has stock in Hyperfine Inc.. Matthew Rosen has stock in Vizma Life Sciences. Matthew Rosen has stock in Intact Data Services. Matthew Rosen has stock in DeepSpin. The institution of Matthew Rosen has received research support from GE HealthCare. The institution of Matthew Rosen has received research support from Imagion Biosystems. Matthew Rosen has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hyperfine Inc.. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from Biogen. The institution of Dr. Kimberly has received research support from NControl Therapeutics. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from American Heart Association. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.